Top

Clinical Research in Cardiology

Published in:

01-05-2010 | Original Paper

Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction

Authors: Katarzyna Korybalska, Małgorzata Pyda, Stefan Grajek, Magdalena Łanocha, Andrzej Bręborowicz, Janusz Witowski

Published in: Clinical Research in Cardiology | Issue 5/2010

Abstract

Background

Monocyte chemoattractant protein-1 (MCP-1) plays a key role in the pathogenesis of atherosclerosis and has been proposed as a biomarker for patients with cardiovascular disease.

Methods

To assess its clinical usefulness, serum MCP-1 concentrations were measured in patients with ST-elevation myocardial infarction (MI) at admission, immediately after percutaneous coronary intervention (PCI), at 24 h, and after 6 months.

Results

We found no differences in MCP-1 concentrations between patients with acute MI, patients with stable coronary artery disease and healthy individuals. Although median MCP-1 concentrations in patients with MI were similar at admission and after 6 months, there were significant differences between individuals in how MCP-1 levels changed with time. As demonstrated by comparing baseline quartiles of MCP-1, the levels of MCP-1 tended to increase in patients with low MCP-1 concentration at admission, and decrease in patients with initially high MCP-1 levels. We found an inverse correlation between MCP-1 concentration at baseline and the time to reperfusion, and detected a significant decrease in MCP-1 concentration immediately after PCI. We also observed lower MCP-1 concentrations over time in patients who developed restenosis within 6 months. However, we did not confirm the association between MCP-1 concentrations at baseline and a number of previously implicated demographic, clinical and laboratory criteria.

Conclusions

Our data demonstrate some new aspects of MCP-1 measurement in patients with MI, but do not corroborate many earlier observations.

Bonaca MP, Morrow DA (2008) Defining a role for novel biomarkers in acute coronary syndromes. Clin Chem 54:1424–1431CrossRefPubMed

O’Donoghue M, Morrow DA (2008) The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol 23:309–314CrossRefPubMed

Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95:858–866CrossRefPubMed

Braunersreuther V, Mach F, Steffens S (2007) The specific role of chemokines in atherosclerosis. Thromb Haemost 97:714–721PubMed

Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K et al (2008) Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28:1909–1919CrossRefPubMed

Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T et al (2007) Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 115:584–592CrossRefPubMed

Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto JP, Morrow DA et al (2004) Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 44:1812–1818CrossRefPubMed

de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM et al (2003) Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107:690–695CrossRefPubMed

Kervinen H, Manttari M, Kaartinen M, Makynen H, Palosuo T, Pulkki K et al (2004) Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol 94:993–996CrossRefPubMed

10.

Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE et al (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41:1460–1467CrossRefPubMed

11.

Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN (2003) Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 338:17–24CrossRefPubMed

12.

Lewandowski M, Kornacewicz-Jach Z, Millo B, Zielonka J, Czechowska M, Kaliszczak R et al (2008) The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol J 15:357–364PubMed

13.

de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS et al (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50:2117–2124CrossRefPubMed

14.

Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE et al (2006) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99:891–899CrossRefPubMed

15.

Morimoto H, Hirose M, Takahashi M, Kawaguchi M, Ise H, Kolattukudy PE et al (2008) MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res 78:554–562CrossRefPubMed

16.

Frangogiannis NG, Shimoni S, Chang SM, Ren G, Shan K, Aggeli C et al (2002) Evidence for an active inflammatory process in the hibernating human myocardium. Am J Pathol 160:1425–1433PubMed

17.

Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al (2005) CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881–889CrossRefPubMed

18.

Dobaczewski M, Frangogiannis NG (2009) Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) 1:391–405

19.

Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al (2002) Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106:2351–2357CrossRefPubMed

20.

Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R et al (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298–305CrossRefPubMed

21.

El Menyar AA (2008) Cytokines and coronary artery disease: the state of the art. Crit Pathw Cardiol 7:139–151PubMed

22.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695CrossRefPubMed

23.

Frangogiannis NG (2007) The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 50:2125–2127CrossRefPubMed

24.

Murakami Y, Kurosaki K, Matsui K, Shimada K, Ikeda U (2003) Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction. Cardiovasc Drugs Ther 17:249–255CrossRefPubMed

25.

Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR et al (2005) Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis risk in communities study. Atherosclerosis 183:301–307CrossRefPubMed

26.

Nishiyama K, Ogawa H, Yasue H, Soejima H, Misumi K, Takazoe K et al (1998) Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 62:710–712CrossRefPubMed

27.

McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr et al (2005) CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the framingham heart study. Circulation 112:1113–1120CrossRefPubMed

28.

Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718–723CrossRefPubMed

29.

Lukacs NW, Strieter RM, Elner V, Evanoff HL, Burdick MD, Kunkel SL (1995) Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood 86:2767–2773PubMed

30.

Hohensinner PJ, Kaun C, Rychli K, Ben Tal CE, Kastl SP, Demyanets S et al (2006) Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett 580:3532–3538CrossRefPubMed

31.

Flamant L, Toffoli S, Raes M, Michiels C (2009) Hypoxia regulates inflammatory gene expression in endothelial cells. Exp Cell Res 315:733–747CrossRefPubMed

32.

Bosco MC, Puppo M, Pastorino S, Mi Z, Melillo G, Massazza S et al (2004) Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol 172:1681–1690PubMed

33.

Negus RP, Turner L, Burke F, Balkwill FR (1998) Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol 63:758–765PubMed

34.

Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, Volger OL et al (2009) Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 46:177–185CrossRefPubMed

35.

Gabrielsen A, Lawler PR, Yongzhong W, Steinbruchel D, Blagoja D, Paulsson-Berne G et al (2007) Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol 42:870–883CrossRefPubMed

36.

Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ et al (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38:12959–12968CrossRefPubMed

37.

Pyda M, Korybalska K, Ksiazek K, Grajek S, Lanocha M, Lesiak M et al (2006) Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 98:902–905CrossRefPubMed

38.

Niu J, Kolattukudy PE (2009) Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 117:95–109CrossRef

39.

Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al (2007) The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204:3037–3047CrossRefPubMed

40.

Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T et al (2009) Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 54:130–138CrossRefPubMed

41.

Sako H, Miura S, Iwata A, Nishikawa H, Kawamura A, Matsuo K et al (2008) Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. Intern Med 47:7–13CrossRefPubMed

42.

Inami N, Nomura S, Shimazu T, Manabe K, Kimura Y, Iwasaka T (2007) Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis 24:267–273CrossRefPubMed

43.

Hognestad A, Endresen K, Wergeland R, Mellembakken JR, Mollnes TE, Omland T et al (2005) Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 24:1026–1032CrossRefPubMed

44.

Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M et al (2001) Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21:327–334PubMed

45.

Usui M, Egashira K, Ohtani K, Kataoka C, Ishibashi M, Hiasa K et al (2002) Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 16:1838–1840PubMed

46.

Toutouzas K, Colombo A, Stefanadis C (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25:1679–1687CrossRefPubMed

47.

Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD (2007) Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 27:929–935CrossRefPubMed

48.

Tarzami ST, Calderon TM, Deguzman A, Lopez L, Kitsis RN, Berman JW (2005) MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G (alphai)-independent pathway. Biochem Biophys Res Commun 335:1008–1016CrossRefPubMed

49.

Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N et al (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80:1095–1100PubMed

50.

Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y et al (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9:178–183PubMed

Title: Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction
Authors: Katarzyna Korybalska
Małgorzata Pyda
Stefan Grajek
Magdalena Łanocha
Andrzej Bręborowicz
Janusz Witowski
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Clinical Research in Cardiology / Issue 5/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-010-0122-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2010

Intrathoracic impedance monitoring detecting pneumonia

The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy

The corrected QT interval in 24 h ECGs in neonates

Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement

Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients

Effects of mild hypothermia on hemodynamics in cardiac arrest survivors and isolated failing human myocardium

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page